Publisher
Springer International Publishing
Reference33 articles.
1. American Psychiatric Association. Bipolar and related disorders. In: American Psychiatric Association (eds). Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC. American Psychiatric Association; 2013.
2. Amon JS, Johnson SB, El-Mallakh RS. Asenapine for the control of physical aggression: a prospective naturalist pilot study. Psychopharmacol Bull. 2017;47:27–32.
3. Bjorkholm C, Franberg O, Malmerfelt A, Marcus MM, Konradsson-Geuken A, Schilstrom B, Jardemark K, De Boer T, Tonnaer JA, De Vos CJ, Van Delft AM. Neurochemical studies with the potential antipsychotic compound trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro1H- dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung. 1990;40:550–4.
4. Björkholm C, Frånberg O, Malmerfelt A, Marcus MM, Konradsson-Geuken Å, Schilström B, Jardemark K, Svensson TH. Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat. Int J Neuropsychopharmacol. 2014;18(3):pyu068. https://doi.org/10.1093/ijnp/pyu068. PMID: 25522408; PMCID: PMC4360248.
5. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63:1762–84.